Clinical

Study finds the use of short-acting opioids decreased and the usage of long-acting opioids increased from January 2014 to March 2016.

A new study suggests that a Web-based intervention could improve a cancer survivor’s cognitive function post treatment.

What we're reading, November 1, 2016: despite law, women in California still struggle to access birth control; Americans mostly believe obesity can be fixed through willpower; and Facebook is going after pharmaceutical advertisements.

A perspective piece, published by researchers from Rutgers University, laments the lack of interest shown by researchers in a clinical trial data-sharing project launched in January 2014.

What we're reading, October 28, 2016: Medicare blocks some efforts to automatically move customers eligible for Medicare into Medicare Advantage; the first lung cancer vaccine developed in Cuba will be tested in the US; and American Red Cross and Teladoc partner for disaster relief.

For millions, the Affordable Care Act promised relief from the expenses of contraception. So why are many still not feeling it?

Long-term follow-up of women who underwent mastectomy and breast reconstruction subsequent to a breast cancer diagnosis found that the success of the procedure and associated complications were not influenced by the woman’s age.

The quality of outpatient care for adults has not improved during the past decade, and in some important areas has worsened, according to a new study published in JAMA Internal Medicine by David M. Levine, MD, of Brigham & Women’s Hospital in Boston, and colleagues.

At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), 2 employer groups and a provider participated on a panel to provide practical insight into the extraordinary challenges and decisions faced by employers and employees with a cancer diagnosis.

What we’re reading, October 24, 2016: Cigna makes it easier for clinicians to prescribe drugs to treat opioid addiction; some hospitals move to eliminate sugary drinks from their campuses; and a researcher at the National Cancer Institute was months late to notify authorities of 2 deaths in the clinical trial he oversaw.